Company intelligence / Profile preview

Gyes B.V.

Utrecht, Utrecht, Netherlandsgyes.com.tw ↗

Ownership: Private
Development stage: Preclinical

Overview

Gyes B.V. is a science-driven biotech start-up focused on pioneering immunotherapy research using its proprietary Multispecific Antibody Platform (MAP). The company targets disease-causing cell subpopulations in cancer, autoimmune, and chronic inflammatory conditions. No clinical results have been published as of the latest available information.[1][2][5]

Therapeutic areas: OncologyImmunology
Modalities: Multispecific antibodiesAntibody therapeutics[1][2][5]
Industry: Biotech

Drug pipeline

1 asset

M300

Pre-clinical

Indications: Cancer

Beyond the preview

Go deeper on Gyes B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gyes B.V..

Explore the full profile